Hydrocodone for cough in advanced cancer

Abstract

Cough is a common symptom in advanced cancer. Hydrocodone is the antitussive of choice in our palliative medicine inpatient unit. We reviewed the pharmacy records for the use of hydrocodone for all cancer admissions to our unit from May 1996 to December 1998. Median treatment duration with hydrocodone was three days (range 1-18). Median maximum daily dose was 15 mg (range 5-100), and median total dose during the hospital stay was 32 mg (range 5-455). Lung cancer as a primary cancer site was strongly related to the use of hydrocodone. The highest median duration of treatment (five days) was for esophageal cancer and the highest median maximum daily dose (35 mg) and total dose (75 mg) were for treating kidney cancer. This retrospective review provides information regarding the use of hydrocodone on the palliative medicine unit of the Cleveland Clinic Foundation. Controlled trials are needed to evaluate the efficacy and safety of hydrocodone for cough in advanced cancer.

Get full access to this article

View all access options for this article.

References

Donnelly S , Walsh D : The symptoms of advanced cancer. Semin Oncol. 1995; 22(2 Suppl 3): 67-72.

Cooke N : Cough. In Walsh TD (ed.): Symptom Control. Oxford, England: Blackwell, 1989; 81-88.

Donnelly S , Walsh D , Rybicki L : The symptoms of advanced cancer: Identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care. 1995; 11: 27-32.

Drug Information for the Health Care Professional, 19th edition. Englewood, Colorado: Micromedex, 1999.

Walsh D , Doona M , Molnar M , Lipnickey V : Symptom control in advanced cancer: Important drugs and routes of administration. Semin Oncol. 2000; 27: 69-83.

Walsh D : Symptom control in advanced cancer. Proceedings of the American Society of Clinical Oncology Conference. Denver, Colorado, May 17-20, 1997: 295-302.

Doona M , Walsh D : Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med. 1997; 12: 55-58.

Glare PA , Walsh TD : Dose ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol. 1993; 11: 973-978.

Landis SH , Murray T , Bolden S , Wingo PA : Cancer statistics, 1998. Ca Cancer J Clin. 1998; 48: 6-29.

10.

Cozzi A , Milanos S , Cancalini G , Zanotelli T , Cosciani M , Cunico S : Survey of lung metastases in renal cell carcinoma. Br J Urol. 1995; 5: 445.

11.

Quint LE , Hepburn LM , Francis IR , Whyte RI , Orringer MB : Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer. 1995; 76: 1120-1125.